Article

News

ARVO 2024: Researchers detail novel glaucoma shunt

Author(s):

In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.

(Image credit: Adobe Stock)

(Image credit: Adobe Stock)

In a study presented this week at the Association for Research in Vision and Ophthalmology (ARVO) 2024 annual meeting in Seattle, a team of researchers introduced a new type of shunt for treating glaucoma that can be adjusted after surgery to control how much fluid flows out of the eye.

According to a news release, this novel shunt could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.1

Ariana Levin, MD, from New York University, along with researchers from Myra Vision in California and the John A. Moran Eye Center in Utah, at ARVO presented a novel shunt that can be opened or closed with a laser.

Levin noted in the news release that researchers developed a novel titratable aqueous shunt for glaucoma therapy designed to allow physicians to increase or decrease the flow of aqueous fluid through the shunt in a slit lamp-based laser procedure.1

“The potential to control aqueous fluid in the postoperative period may allow physicians to personalize care for every patient and potentially improve the safety and efficacy of glaucoma surgery,” she said in the news release.

Reference
The Association for Research in Vision and Ophthalmology-. www.arvo.org. Accessed May 6, 2024. https://www.arvo.org/About/press-room/press-room/novel-glaucoma-shunt-breakthrough/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
© 2025 MJH Life Sciences

All rights reserved.